In unexpected blow, Merck halts Keytruda myeloma trial enrollment to probe patient deaths
admin 13th June 2017 Uncategorised 0The streak of positive Keytruda updates had to end somewhere. After an onslaught of upbeat trial results and regulatory news, maker Merck Monday night announced that it was pausing enrollment on a pair of phase 3 multiple myeloma studies to investigate patient deaths.
More: In unexpected blow, Merck halts Keytruda myeloma trial enrollment to probe patient deaths
Source: fierce